(Q42272479)

19 October 2017

title

Cost-effectiveness analysis of triple therapy with protease inhibitors in treatment-naive hepatitis C patients (English)

1 reference

cost-effectiveness analysis

19 October 2017

main subject

1 reference

inferred from title

author name string

Antonio Blázquez-Pérez

series ordinal

1

1 reference

19 October 2017

Ramón San Miguel

series ordinal

2

1 reference

19 October 2017

Javier Mar

series ordinal

3

1 reference

19 October 2017

publication date

1 October 2013

1 reference

19 October 2017

1 reference

19 October 2017

volume

31

1 reference

19 October 2017

issue

10

1 reference

19 October 2017

page(s)

919-931

1 reference

https://scigraph.springernature.com/pub.10.1007/s40273-013-0080-3

19 October 2017

exact match

0 references

cites work

The prevalence of hepatitis C virus infection in the United States, 1988 through 1994

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0080-3

Epidemiology of hepatitis C: geographic differences and temporal trends

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0080-3

An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0080-3

Boceprevir for untreated chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0080-3

Telaprevir for previously untreated chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0080-3

Factors that predict response of patients with hepatitis C virus infection to boceprevir

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0080-3

Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0080-3

Financial impact of two different ways of evaluating early virological response to peginterferon-alpha-2b plus ribavirin therapy in treatment-naive patients with chronic hepatitis C virus genotype 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0080-3

Cost-effectiveness analysis of therapeutic strategies for patients with chronic hepatitis C previously not responding to interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0080-3

Dermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting antivirals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0080-3

Boceprevir and telaprevir for the treatment of chronic hepatitis C: safety management in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0080-3

Cost effectiveness of interferon alpha or peginterferon alpha with ribavirin for histologically mild chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0080-3

Markov models in medical decision making: a practical guide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0080-3

Structural frameworks and key model parameters in cost-effectiveness analyses for current and future treatments of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0080-3

Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0080-3

Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0080-3

Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0080-3

Empirically calibrated model of hepatitis C virus infection in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0080-3

New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0080-3

Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0080-3

Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0080-3

Bayesian value-of-information analysis. An application to a policy model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0080-3

Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0080-3

Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-013-0080-3

In search of power and significance: issues in the design and analysis of stochastic cost-effectiveness studies in health care

21 January 2018

1 reference

12 December 2020

[Cost effectiveness of the treatment of chronic hepatitis C with interferon-alpha]

1 reference

12 December 2020

Formulary management of the protease inhibitors boceprevir and telaprevir for chronic hepatitis C virus

1 reference

12 December 2020

[What is an efficient health technology in Spain?]

1 reference

12 December 2020

EASL International Consensus Conference on Hepatitis C. Paris, 26-28, February 1999, Consensus Statement. European Association for the Study of the Liver

1 reference

12 December 2020

2011 European Association of the Study of the Liver hepatitis C virus clinical practice guidelines

1 reference

12 December 2020

10.1007/S40273-013-0080-3

Identifiers

DOI

1 reference

Dimensions Publication ID

19 October 2017

1049036992

0 references

1 reference